Eye recommendations
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
| Anti-vascular endothelial growth factor therapies (bevacizumab or ranibizumab) as an adjunct to vitrectomy in diabetic retinopathy (NETAG) | Recommendation | Not recommended | 07/07/2009 | |
| Bevacizumab (Avastin®) for age-related macular degeneration (Updated) | Recommendation | Recommended as an option | 09/09/2014 | |
| Bevacizumab (Avastin®) for diabetic macular oedema (NETAG) | Recommendation | Not recommended | 10/07/2012 | |
| Bevacizumab (Avastin®) for neovascular glaucoma secondary to central retinal vein occlusion (NETAG) | Recommendation | Not recommended | 12/04/2011 | |
| Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for macular oedema secondary to retinal vein occlusion(s)(NETAG) | Recommendation | Bevacizumab (Avastin®) 1.25 mg using a ‘when required’ (PRN) regimen is recommended for management of macular oedema secondary to retinal vein occlusion | 18/01/2011 | |
| Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for non-AMD choriodal neovascular disease (NETAG) | Recommendation Treatment guidelines | Recommends bevacizumab intravitreal injection using a ‘when required’ dose regimen for the treatment of non-AMD CNV, as described in the North East Retinal Group treatment guideline | 08/10/2009 | |
| High dose multivitamins and minerals for the prevention of progression of age-related macular degeneration | Recommendation | Not recommended | 03/06/2014 | |
| Intraocular telescope by VisionCare™ for age-related macular degeneration (NETAG) | Recommendation | Not recommended | 13/11/2012 | |
| Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion | Recommendation RVO treatment pathway | Recommended | 09/09/2014 | |
| Verteporfin (Visudyne®) with photo-dynamic therapy for chronic central serous chorioretinopathy | Updated recommendation | Recommended | 02/06/2020 |